Combodart

Combodart is a combination prescription medicine used to treat the symptoms of benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate, in adult men. Each capsule contains two active ingredients: dutasteride 500 micrograms and tamsulosin hydrochloride 400 micrograms. Together, these two drugs work through complementary mechanisms to relieve urinary symptoms and reduce the risk of disease progression more effectively than either medicine can achieve when used alone.

How Combodart Works

Dutasteride belongs to a class of medicines called 5-alpha reductase inhibitors (5-ARIs). It works by blocking the enzyme responsible for converting testosterone into dihydrotestosterone (DHT), the hormone that drives prostate growth. By reducing DHT levels, dutasteride causes the prostate gland to shrink gradually over several months, reducing the mechanical obstruction to urinary flow.

Tamsulosin hydrochloride is an alpha-1 adrenoceptor blocker. It acts by relaxing the smooth muscle in the prostate and the neck of the bladder, which reduces the dynamic component of urinary obstruction. Unlike dutasteride, tamsulosin produces symptomatic relief relatively quickly, often within days to weeks of starting treatment.

Clinical Benefits

Clinical trials, including the landmark CombAT study, demonstrated that the combination of dutasteride and tamsulosin is significantly superior to either monotherapy for improving urinary symptom scores, increasing maximum urinary flow rate, and reducing the risk of acute urinary retention and the need for surgical intervention. Men with larger prostate volumes and higher PSA levels tend to derive the greatest benefit from combination therapy.

Combodart is a convenient once-daily capsule that simplifies treatment for men who are already using or would benefit from both medicines. It is typically prescribed for men with a prostate volume of at least 30 mL who remain symptomatic on an alpha-blocker alone or who are at increased risk of BPH progression. Treatment duration is generally long-term, as the benefits of dutasteride on prostate volume take time to become fully established and are maintained with continued use.

Combodart is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia in adult men, particularly those with an enlarged prostate who are at risk of disease progression. It is suitable for men in whom monotherapy with either an alpha-blocker or a 5-alpha reductase inhibitor has not provided adequate relief, or for those in whom combination treatment is considered the most appropriate first approach based on prostate size, symptom severity, and PSA level.

How to Take Combodart

Combodart capsules should be swallowed whole with a sufficient amount of water, approximately 30 minutes after the same meal each day. This helps to maintain consistent plasma levels and reduces the likelihood of gastrointestinal discomfort. The capsules must not be opened, crushed, or chewed, as dutasteride is absorbed through the skin and mucous membranes and may pose a risk to pregnant women or women of childbearing potential who come into contact with the contents.

Important Monitoring Considerations

Before starting treatment, a baseline PSA measurement should be taken and a digital rectal examination performed to help exclude prostate cancer. It is important for both patients and clinicians to be aware that dutasteride suppresses PSA levels by approximately 50% after six months of treatment. Any confirmed increase in PSA whilst on Combodart should be investigated, as the expected suppression may mask an underlying malignancy. Patients should carry a card or note indicating they are taking Combodart to ensure their PSA results are interpreted correctly by any healthcare professional involved in their care.

Regular monitoring of urinary symptoms and prostate-specific antigen is recommended during long-term treatment.

The standard dose of Combodart is one capsule (dutasteride 500 micrograms / tamsulosin hydrochloride 400 micrograms) taken orally once daily, ideally at the same time each day after a meal. No dose adjustment is required for elderly patients, as clinical trials included a broad age range without significant differences in efficacy or tolerability.

Combodart is not recommended for patients with severe renal impairment (creatinine clearance below 10 mL/min) and should be used with caution in those with moderate to severe hepatic impairment, as both dutasteride and tamsulosin are hepatically metabolised. No specific dose adjustment is generally required for mild to moderate renal impairment.

If a dose is missed, it should be taken as soon as the patient remembers, provided it is on the same day. If the next day has already begun, the missed dose should be skipped and the regular schedule resumed. Patients should not double up doses to compensate for a missed one. Combodart is not indicated for use in women or children.

Combodart is generally well tolerated, but as with all medicines, it can cause side effects. The following information covers the most commonly reported adverse reactions associated with both dutasteride and tamsulosin.

Common Side Effects

• Ejaculation disorders, including reduced or absent ejaculation (retrograde ejaculation is particularly associated with tamsulosin)
• Decreased libido (reduced sex drive)
• Erectile dysfunction or difficulty maintaining an erection
• Dizziness, which may reflect mild postural hypotension, particularly after the first dose
• Breast tenderness or enlargement (gynaecomastia), associated with dutasteride-induced hormonal changes
• Nasal congestion or runny nose

Serious Side Effects

Patients should seek prompt medical attention if they experience any of the following:

• Severe allergic reactions: symptoms may include rash, itching, swelling of the face, lips, tongue or throat, and difficulty breathing — these reactions are rare but require immediate medical assessment
• Intraoperative floppy iris syndrome (IFIS): tamsulosin can affect the dilator muscle of the iris; patients must inform their ophthalmologist that they are taking or have taken tamsulosin before any cataract surgery, as IFIS can complicate the procedure
• Postural hypotension: a significant fall in blood pressure upon standing, causing dizziness or fainting, particularly in the first hours after dosing or when combined with antihypertensive medicines or phosphodiesterase-5 inhibitors
• Prostate cancer detection: dutasteride reduces PSA levels, which may affect prostate cancer screening; any net increase in PSA warrants further evaluation
• Liver disorders: jaundice or raised liver enzymes have been reported rarely

If any sexual side effects are particularly distressing or persistent, patients should discuss these with their prescriber. Some effects, such as ejaculation disorders, may not resolve after stopping treatment.

Combodart carries several important warnings that patients and prescribers should be aware of before and during treatment.

Risk of Prostate Cancer and PSA Monitoring

Because dutasteride suppresses serum PSA by approximately 50%, the expected PSA reference ranges do not apply to men taking Combodart. Any sustained rise in PSA while on treatment should be evaluated carefully, as it may indicate the presence of prostate cancer. Clinicians should be aware that dutasteride may increase the detection of low-grade prostate cancers while potentially masking high-grade disease in some cases. The medicine is not approved for use in prostate cancer prevention.

Cardiovascular and Surgical Precautions

Tamsulosin can cause postural hypotension, particularly in the early stages of treatment or following dose interruptions. Patients should be advised to rise slowly from a seated or lying position and to avoid driving or operating machinery if they experience dizziness. The combination of tamsulosin with antihypertensive agents, PDE-5 inhibitors such as sildenafil or tadalafil, or other alpha-blockers should be approached with caution due to additive hypotensive effects.

Men scheduled for cataract surgery must inform their ophthalmologist that they are taking or have taken Combodart. Tamsulosin has been associated with intraoperative floppy iris syndrome, which can significantly complicate surgical technique. Discontinuing the medicine before surgery may not reliably prevent this risk.

Combodart must not be used by women. Dutasteride is absorbed through the skin, and pregnant women or those who may become pregnant must not handle broken or leaking capsules.

Combodart must not be used in the following circumstances:

• Known hypersensitivity to dutasteride, tamsulosin, other 5-alpha reductase inhibitors, other alpha-blockers, or any of the excipients
• Use in women or children (the product is indicated only for adult men)
• Severe hepatic impairment, as both active ingredients are extensively metabolised by the liver
• Severe renal impairment (creatinine clearance below 10 mL/min), for tamsulosin component
• History of orthostatic hypotension
• Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) combined with strong CYP2D6 inhibitors (e.g., paroxetine), due to significant risk of elevated tamsulosin plasma levels
• Concomitant use with other alpha-1 blockers
• Patients who are scheduled for cataract surgery should be counselled prior to initiation regarding IFIS risk